Exelon Patch, Extended Release
Product Images NDC 66758-142

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Exelon (NDC 66758-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

13.3mgcarton (13.3mgcarton.jpg)

The package label for Exelon Patch 13.3 mg/24 hours, a rivastigmine transdermal system for prescription use. The label shows that the carton contains 30 extended-release transdermal patches and is labeled for Sandoz Inc. Instructions for discarding used patches and storage details are included, along with barcodes and regulatory information.*

FDA Label Image

4.6mgcarton (4.6mgcarton)

Exelon Patch 4.6 mg/24 hours extended-release transdermal system packaging label by Sandoz Inc. The carton is designed to contain 30 systems, with clear instructions for use and disposal, warnings, and storage information. The label includes barcodes, lot, expiration details, and prominently features the product name and strength.*

FDA Label Image

9.5mgcarton (9.5mgcarton)

Exelon Patch 9.5 mg/24 hours packaging label for the rivastigmine transdermal system. The label indicates the product contains 30 systems intended for transdermal use only, is Rx only, and is distributed by Sandoz Inc. The carton includes usage instructions and disposal information. Barcodes and regulatory info such as the NDC number 66758-143-31 are visible.*

FDA Label Image

Rivastigmine Chemical Structure (Exelon Patch 01)

Chemical structure of rivastigmine, the active ingredient in Exelon. The diagram shows the molecular arrangement and bonds characteristic of this compound used in the extended-release transdermal patch form by Sandoz Inc.*

FDA Label Image

Figure 1: Cross Section Of The Exelon Patch (Exelon Patch 02)

An instructional diagram showing a cross-sectional view of a transdermal patch with four labeled layers (Layers 1 to 4). Below the patch, two dimples on either side are highlighted, indicating specific features of the patch design.*

FDA Label Image

Figure 2: Rivastigmine Plasma Concentrations Following Dermal 24-hour Patch Application (Exelon Patch 03)

A line graph showing plasma rivastigmine concentration (ng/mL) over 24 hours for three dosing strengths of Exelon patch extended-release: 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. The graph plots rivastigmine levels on the vertical axis and time in hours on the horizontal axis, illustrating pharmacokinetic profiles for each dose strength.*

FDA Label Image

Figure 3: Time Course Of The Change From Baseline In Adas-cog Score For Patients Observed At Each Time Point (Exelon Patch 04)

A line graph showing least square means change from baseline ADAS-Cog rating over 24 weeks of treatment. The x-axis represents weeks during treatment (0, 16, 24), and the y-axis shows change from baseline rating from clinical improvement to clinical decline. Four lines compare rivastigmine 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo groups, with error bars representing SEM.*

FDA Label Image

Figure 4: Distribution Of Adcs-cgic Scores For Patients Completing The Study (Exelon Patch 05)

A bar chart showing the distribution of ADCS-CGIC ratings among patients using different treatments, including 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, 6 mg capsules twice daily, and placebo. The vertical axis represents the percentage of patients, and the horizontal axis categorizes ratings from markedly improved to markedly worse.*

FDA Label Image

Cut The Pouch Along The Dotted Line And Remove The Patch. (Exelon Patch 07)

Illustration showing proper application sites for the Exelon (rivastigmine) transdermal patch. It depicts shaded areas indicating acceptable patch placement on the left or right upper arm, left or right side of the chest, left or right upper back, and left or right lower back of a human body.*

FDA Label Image

Put The Sticky Side Of The Patch On The Upper Or Lower Back, Upper Arm Or Chest And Then Peel Off The Second Side Of The Protective Liner. (Exelon Patch 09)

An instructional diagram showing a hand peeling off the protective liners from the sticky surface of a transdermal patch, labeled as such. The illustration highlights the process of preparing the patch for application, associated with the Exelon rivastigmine extended-release transdermal patch.*

FDA Label Image

Press The Patch Firmly In Place With The Hand To Make Sure That The Edges Stick Well. (Exelon Patch 0a)

An instructional line drawing showing the application of a transdermal patch on the upper back of a person. The illustration depicts hands in the process of placing or removing the patch on the skin, consistent with a usage guide for a transdermal drug delivery system.*

FDA Label Image

Figure 5 Time Course Of The Change From Double-blind Baseline In Adcs-iadl Score For Patients Observed At Each Time Point In Study 2 (Exelon Patch 0d)

A line graph depicting ADCS-ADL change from baseline over 52 weeks of treatment with Exelon Patch at 13.3 mg/24h and 9.5 mg/24h doses. The graph shows clinical decline trends, with the 13.3 mg/24h dose generally resulting in less decline compared to 9.5 mg/24h. Statistical significance markers indicate differences between doses at selected time points.*

FDA Label Image

Figure 6 Time Course Of The Change From Double-blind Baseline In Adas-cog Score For Patients Observed At Each Time Point In Study 2 (Exelon Patch 0e)

A line graph depicting the change from baseline in ADAS-Cog scores over 52 weeks of treatment with Exelon Patch at 13.3 mg/24hr and 9.5 mg/24hr doses. The vertical axis shows ADAS-Cog change with clinical improvement upward and clinical decline downward. The horizontal axis represents weeks of treatment. Data points include means and standard error of the mean (SEM).*

FDA Label Image

Figure 7 Time Course Of The Change From Baseline In Sib Score For Patients Observed At Each Time Point (modified Full Analysis Set–locf) (Exelon Patch 0g)

Line graph depicting least squares mean change with standard error over 24 weeks of treatment comparing rivastigmine patch 15 cm² and 5 cm². The y-axis shows the mean change ranging from clinical improvement to decline, and the x-axis shows weeks of treatment. Data points include statistical significance annotations for 16 and 24 weeks, with rivastigmine patch 15 cm² showing less decline than 5 cm² patch.*

FDA Label Image

Figure 8 Time Course Of The Change From Baseline In Adcs-adl-siv Score For Patients Observed At Each Time Point (modified Full Analysis Set – Locf) (Exelon Patch 0h)

A line graph depicting least squares mean changes ± STE over 24 weeks of treatment with rivastigmine patches at two sizes, 15 cm² and 5 cm². The vertical axis shows LS mean change indicating clinical improvement and decline, while the horizontal axis represents weeks of treatment at 0, 8, 16, and 24 weeks. Statistical values and significance levels are included above data points.*

FDA Label Image

Figure F (Exelon Patch 0i)

An instructional illustration showing the proper application of a transdermal patch on the upper back of a person. One hand is positioning the patch along the center of the back, just below the neck area.*

FDA Label Image

Figure G (Exelon Patch 0j)

An instructional illustration showing a person applying a transdermal patch to the upper chest area. One hand is holding the patch while the other hand peels off the backing, demonstrating how to properly place the patch on the skin.*

FDA Label Image

Figurea (Figurea)

An instructional illustration showing the components of the Exelon Patch (rivastigmine transdermal system) packaging. It displays the pouch containing the patch, the patch labeled with 'EXELON PATCH,' protective liners, adhesive with medicine, and outside backing, highlighting the patch's layered design for transdermal drug delivery.*

FDA Label Image

Figurec (Figurec)

An instructional illustration showing a hand holding an Exelon Patch (rivastigmine transdermal system) packet while scissors cut along the edge to open it. The visible text includes the brand name Exelon Patch, the active ingredient rivastigmine transdermal system, and directions stating it is for transdermal use only and contains one system.*

FDA Label Image

Figureh (Figureh)

Instructional illustration for disposal of the Exelon rivastigmine transdermal extended-release patch. The three panels show folding the sticky sides of the patch together, placing the folded patch into the original empty pouch, and then disposing of the pouch in the trash while keeping it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.